Determinants of the optimal first-line therapy for follicular lymphoma: A decision analysis

被引:13
作者
Olin, Rebecca L.
Kanetsky, Peter A. [2 ]
Ten Have, Thomas R. [2 ]
Nasta, Sunita D. [3 ]
Schuster, Stephen J. [3 ]
Andreadis, Charalambos [1 ]
机构
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Adult Bone Marrow Transplantat Program, San Francisco, CA 94143 USA
[2] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
关键词
BONE-MARROW-TRANSPLANTATION; QUALITY-OF-LIFE; MANTLE CELL LYMPHOMAS; COST-EFFECTIVENESS; CHOP CHEMOTHERAPY; HIGH-RISK; PHASE-II; RITUXIMAB; CYCLOPHOSPHAMIDE; COMBINATION;
D O I
10.1002/ajh.21655
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combination immunochemotherapy is the most common approach for initial therapy of patients with advanced-stage follicular lymphoma, but no consensus exists as to the optimal selection or sequence of available regimens. We undertook this decision analysis to systematically evaluate the parameters affecting the choice of early therapy in patients with this disease. We designed a Markov model incorporating the three most commonly utilized regimens (RCVP, RCHOP, and RFIu) in combinations of first- and second-line therapies, with the endpoint of number of quality-adjusted life years (QALYs) until disease progression. Data sources included Phase II and Phase III trials and literature estimates of long-term toxicities and health state utilities. Meta-analytic methods were used to derive the values and ranges of regimen-related parameters. Based on our model, the strategy associated with the greatest number of expected quality-adjusted life years was treatment with RCHOP in first-line therapy followed by treatment with RFIu in second-line therapy (9.00 OALYs). Strategies containing RCVP either in first- or second-line therapy resulted in the lowest number of QALYs (range 6.24-7.71). Sensitivity analysis used to determine the relative contribution of each model parameter identified PFS after first-line therapy and not short-term QOL as the most important factor in prolonging overall quality-adjusted life years. Our results suggest that regimens associated with a longer PFS provide a greater number of total QALYs, despite their short-term toxicities. For patients without contraindications to any of these regimens, use of a more active regimen may maximize overall quality of life. Am. J. Hematol. 85:255-260, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 47 条
[1]   Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma [J].
Al-Tourah, Abdulwahab J. ;
Gill, Karamjit K. ;
Chhanabhai, Mukesh ;
Hoskins, Paul J. ;
Klasa, Richard J. ;
Savage, Kerry J. ;
Sehn, Laurie H. ;
Shenkier, Tamara N. ;
Gascoyne, Randy D. ;
Connors, Joseph M. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5165-5169
[2]  
[Anonymous], 2008, NATL VITAL STAT REPO
[3]  
[Anonymous], 1980, CLIN DECISION ANAL
[4]   Anthracycline-induced chronic cardiotoxicity and heart failure [J].
Appel, Jon M. ;
Nielsen, Dorte ;
Zerahn, Bo ;
Jensen, Benny V. ;
Skagen, Knud .
ACTA ONCOLOGICA, 2007, 46 (05) :576-580
[5]   A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome [J].
Cutler, CS ;
Lee, SJ ;
Greenberg, P ;
Deeg, HJ ;
Pérez, WS ;
Anasetti, C ;
Bolwell, BJ ;
Cairo, MS ;
Gale, RP ;
Klein, JP ;
Lazarus, HM ;
Liesveld, JL ;
McCarthy, PL ;
Milone, GA ;
Rizzo, JD ;
Schultz, KR ;
Trigg, ME ;
Keating, A ;
Weisdorf, DJ ;
Antin, JH ;
Horowitz, MM .
BLOOD, 2004, 104 (02) :579-585
[6]   Purine analogue combinations for indolent lymphomas [J].
Di Bella, N ;
Ravandi, F .
SEMINARS IN HEMATOLOGY, 2006, 43 (02) :S11-S21
[7]  
Domingo-Domènech E, 2002, HAEMATOLOGICA, V87, P1229
[8]   Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy [J].
Doorduijn, J ;
Buijt, I ;
Holt, B ;
Steijaert, M ;
Uyl-de Groot, C ;
Sonneveld, P .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (02) :116-123
[9]  
Economopoulos Theofanis, 2003, Hematol J, V4, P110, DOI 10.1038/sj.thj.6200229
[10]   The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].
Forstpointner, R ;
Dreyling, M ;
Repp, R ;
Hermann, S ;
Hänel, A ;
Metzner, B ;
Pott, C ;
Hartmann, F ;
Rothmann, F ;
Rohrberg, R ;
Böck, HP ;
Wandt, H ;
Unterhalt, M ;
Hiddemann, W .
BLOOD, 2004, 104 (10) :3064-3071